Triglyceride deposit cardiomyovasculopathy (TGCV) is a rare and intractable disease, first reported in Japanese patients with congestive heart failure (HF) requiring heart transplant. TGCV is characterized by the excessive accumulation of triglyceride (TG) in cardiomyocytes and vascular smooth muscle cells, which leads to coronary artery disease, HF, and arrhythmia. In TGCV, long-chain fatty acid (LCFA), a major energy source for the normal heart, accumulates as TG in cytoplasmic lipid droplets. In 2009, we launched the Japan TGCV study group to elucidate the pathophysiology of TGCV and have developed diagnostic procedures along with specific treatment. Single-photon emission computed tomography (SPECT) with iodine-123-β-methyl iodophenylpentadecanoic acid (BMIPP), a radioactive analogue for LCFA, is a useful diagnostic tool to detect impaired myocardial LCFA metabolism in TGCV. Since we posted the latest version of diagnostic criteria including the myocardial washout rate of BMIPP in SPECT in 2016, we have identified 138 patients with TGCV, 27 of whom have died. More recently, we developed a TGCV severity score consisting of specific questionnaires in order to assess symptoms and activities of daily living in patients with TGCV.
T riglyceride deposit cardiomyovasculopathy (TGCV) is a novel disease concept that was discovered in Japanese cardiac transplant recipients (1) . Patients with TGCV have severe heart failure (HF), arrhythmia, and coronary artery disease (CAD) (1) (2) (3) . Based on our clinical studies, the diagnostic criteria for TGCV have been reported by the Japan TGCV study group, where the increasing importance of iodine-123-β-methyl iodophenyl-pentadecanoic acid (BMIPP) single-photon emission computed tomography (SPECT) has been clarified. Here, we provide current information on TGCV and the activities of the Japan TGCV study group.
Definition, classification, and pathophysiology of TGCV
The phenotype of TGCV was primarily reported in patients with severe HF and genetic mutations of adipose triglyceride lipase (ATGL) (1) , which is a rate-limiting enzyme for intracellular hydrolysis of TG and release of long-chain fatty acid (LCFA) as a major cardiac energy source (4) . TGCV is characterized by excessive TG accumulation in both myocardium and coronary arteries, and the subtypes are classified into primary TGCV (P-TGCV, with ATGL mutations) and idiopathic TGCV (I-TGCV, without ATGL mutations) (5) .
Genetic causes and etiologies of the latter are unknown. I-TGCV was initially identified in the autopsied study with diabetic patients (6) and we recently reported that ATGL activities in peripheral leukocytes were markedly reduced in some patients with I-TGCV (7). In TGCV, abnormal metabolism of intracellular TG and LCFA such as ATGL dysfunction leads to lipotoxicity and energy failure in affected cells and tissues, resulting in HF, CAD, and arrhythmia (3, 7) .
Latest version of diagnostic criteria for TGCV and number of patients identified
In September 2016, we posted the latest version of diagnostic criteria for TGCV (8) . As shown in Table 1 , these criteria include 2 major items (2 points each) and 2 minor items (1 point each). Four points or more and 3 points indicate definite and probable TGCV, respectively. The major items refer to TG deposition in myocardium and coronary arteries, which is the pathological basis of TGCV. The two minor items are Jordans' anomaly (9, 10) and diabetes mellitus. To date, 138 patients with TGCV have been identified from 7 institutes and hospitals in Japan. Unfortunately, 27 patients have died.
These data indicate that TGCV is a rare and intractable Miyauchi et (a) For tissue TG contents examination, frozen sections with osmium fixation, but not paraffin sections, should be used for prevention of lipid elution (b) The presence or absence of a significant stenosis is not considered (c) For difficult cases, May-Giemsa staining slides of peripheral blood smear will be evaluated by the Japan TGCV study group (d) According to the diagnostic criteria of DM by the Japan Diabetes Society (e) If no opportunity for genetic analyses for ATGL (i.e ., deceased cases), the Japan TGCV study group can judge under clinicopathological datasets Please feel free to contact our study group (E-mail: info@tgcv.org) cardiovascular disease.
Significance of washout rate of BMIPP-SPECT in the diagnosis of TGCV
BMIPP-SPECT is used to evaluate metabolism of LCFA in cardiomyocytes (11) . LCFA is an essential energy source of the normal heart. After LCFA is taken up by cardiomyocytes, it is either synthesized to TG or being underwent beta oxidation to be energy-utilized, and BMIPP takes similar intracellular dynamics (11, 12) . However, in patients with TGCV, once LCFA is pooled as TG, it remains inside the cell without being hydrolyzed (3) . Hence, patients with TGCV have markedly decreased washout rate (WOR) of BMIPP (13), which is unrelated to local myocardial uptake abnormality 
Detection of myocardial small lipid droplets
In some cases with TGCV, lipid droplets in cardiomyocytes are too small to be detected by lipid staining such as Oil red O.
Hara et al. reported that the overexpression of perilipin (PLIN)
2, a lipid droplet maintenance protein, was a possible biomarker candidate in the context of lipid metabolism using fibroblasts from TGCV patients (17) . Therefore, we can detect small lipid droplets as a PLIN 2 protein mass in cardiomyocytes (Fig. 2B) , indicating that PLIN 2 may be a useful histological protein marker for cardiomyocyte steatosis.
Differential diagnosis of TGCV
It is important to differentiate TGCV from other cardiovascular diseases as follows: dilated cardiomyopathy, hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy, mitochondrial cardiomyopathy, alcoholic heart disease, metabolic myocardial disorders (e. g., Fabry disease, Pompe disease, and cholesteryl ester storage disease).
Furthermore, because a mild reduction of BMIPP WOR was reported in chronic hemodialysis patients (18) , it would be of interest to know whether TGCV phenotype might exist among patients with chronic kidney disease, as reported in our postmortem study (6) .
Development of severity score for TGCV
In order to assess symptoms of this newly identified disease, we collected clinical symptoms through interviews with TGCV outpatients in the Osaka University Hospital. Based upon the information, we developed 2 sets of TGCV-specific questionnaires: One set is for symptoms (the upper panel in Table 2 ) and the other for activities of daily living (ADL) (the lower panel in Table 2 ).
The former includes 4 sections as follows: 1) ischemic heart symptoms, 2) arrhythmia symptoms, 3) heart failure or energy failure symptoms, and 4) peripheral symptoms. Each section includes 3-5 questions (Qs). The point for each answer ranges from 0 (Never) to 4 (Always) (please see the footnote of the upper panel). As shown in Table 2 Table 2 , the severity score for ADL is summed as that for symptoms.
The significance of patient-reported outcomes has been acknowledged for the assessment of clinical trials and development of therapy (19, 20) . Although it is necessary to examine the reliability and validity of the questionnaires and Histopathological examinations of myocardial biopsy, surgically resected myocardium, and explanted heart directly demonstrate the accumulation of TG in the myocardium. For examination under light microscopy, the myocardial specimens are immediately fixed with 10% formalin, stored at room temperature, embedded in paraffin, cut into 4-μm sections and stained with H&E, and immunohistochemical staining is performed for perilipin 2. A histological section stained with H&E demonstrates many small vacuoles that are suggestive of prominent lipid droplets in the cytoplasm of cardiomyocytes (A) in a 62-year-old patient with idiopathic TGCV.
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